
|Articles|June 22, 2011
- Psychiatric Times Vol 28 No 6
- Volume 28
- Issue 6
Einstein’s Happiest Moment -for Susanne
Author(s)Richard M. Berlin, MD
"Einstein’s happiest moment...occurred when he realized...a falling man falling...beside a falling apple..."
Advertisement
POETRY OF THE TIMES
Einstein’s happiest moment
occurred when he realized
a falling man falling
beside a falling apple
could also be described
as an apple and a man at rest
while the world rises around them.
And my happiest moment
occurred when I realized
you were falling for me,
right down to the core, and the rest,
relatively speaking, has flown past
faster than the speed of light.
Articles in this issue
over 15 years ago
Feeling Socially Safeover 15 years ago
Avoiding SRI Discontinuation Syndromeover 15 years ago
Drs McGlashan and Woods Respond to Dr Feinbergover 15 years ago
Obama Drug Misuse Strategy Targets Physician Educationover 15 years ago
Alfred M. Freedman, MD, 1917-2011over 15 years ago
Is It Treatment-Refractory Schizophrenia . . . And if It Is?over 15 years ago
Are We Training Psychiatrists to Provide Only Medication Management?over 15 years ago
Effects of Early Parental DepressionAdvertisement
Related to this article

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5

